Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Multiple Myeloma × Dosage Forms × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Solid Tumors 1 Recurrence 1 Prostatic Neoplasms 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Myelodysplastic Syndromes 1 Multiple Myeloma 1 Leukemia, Myeloid, Acute 1 Leukemia 1 Advanced Solid Tumors 1

Interventions

Dexamethasone 128 Lenalidomide 70 Cyclophosphamide 69 Bortezomib 68 Calcium Dobesilate 50 fludarabine 44 pomalidomide 40 daratumumab 37 carfilzomib 33 fludarabine phosphate 30 Melphalan 25 dexamethasone acetate 20 dexamethasone 21-phosphate 20 auricularum 18 Filgrastim 18 Whole-Body Irradiation 14 Biopsy 13 isatuximab 12 Vorinostat 12 Tacrolimus 12 Peripheral Blood Stem Cell Transplantation 12 Magnetic Resonance Spectroscopy 12 Granulocyte Colony-Stimulating Factor 12 Specimen Handling 11 ixazomib 10 Sirolimus 10 Panobinostat 10 Mycophenolic Acid 10 Cyclosporine 10 venetoclax 9

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02939183 2024-09-26

INTREPID-1

Amgen

Phase 1 Completed

61 enrolled 28 charts

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡